Trial Profile
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs MVI 816 (Primary) ; Nivolumab (Primary) ; Sargramostim (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 01 Jun 2023 Planned End Date changed from 31 Jan 2025 to 1 Nov 2023.
- 13 Sep 2022 Status changed to discontinued , according to Results presented at the 47th European Society for Medical Oncology Congress